PLAC1 and cancer: From a therapeutic perspective, our data not only suggest that Plac1 may be a potential drug target, but that chemokine receptor antagonists developed for chronic inflammatory disorders, including COPD and psoriasis45,46, may be useful adjuvants when used in combination with other therapies to enhance the efficacy of cancer treatment47,48.